Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.

Abstract:

:A series of oxyguanidine analogues of the cysteine protease inhibitor WRR-483 were synthesized and evaluated against cruzain, the major cysteine protease of the protozoan parasite Trypanosoma cruzi. Kinetic analyses of these analogues indicated that they have comparable potency to previously prepared vinyl sulfone cruzain inhibitors. Co-crystal structures of the oxyguanidine analogues WRR-666 (4) and WRR-669 (7) bound to cruzain demonstrated different binding interactions with the cysteine protease, depending on the aryl moiety of the P1' inhibitor subunit. Specifically, these data demonstrate that WRR-669 is bound noncovalently in the crystal structure. This represents a rare example of noncovalent inhibition of a cysteine protease by a vinyl sulfone inhibitor.

journal_name

ACS Med Chem Lett

authors

Jones BD,Tochowicz A,Tang Y,Cameron MD,McCall LI,Hirata K,Siqueira-Neto JL,Reed SL,McKerrow JH,Roush WR

doi

10.1021/acsmedchemlett.5b00336

subject

Has Abstract

pub_date

2015-12-15 00:00:00

pages

77-82

issue

1

issn

1948-5875

journal_volume

7

pub_type

杂志文章
  • Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides.

    abstract::Using a multiplexed, reporter gene-based, high-throughput screen, we identified 9-fluoro-7-hydroxy-3-methyl-5-oxo-N-(pyridin-3-ylmethyl)-2,3-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-6-carboxamide as a TLR2 agonist. Preliminary structure-activity relationship studies on the carboxamide moiety led to the identification o...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00540

    authors: Hu Z,Banothu J,Beesu M,Gustafson CJ,Brush MJH,Trautman KL,Salyer ACD,Pathakumari B,David SA

    更新日期:2018-12-20 00:00:00

  • Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.

    abstract::B-cell lymphoma 6 (BCL6) is a transcriptional repressor frequently deregulated in lymphoid malignancies. BCL6 engages with number of corepressors, and these protein-protein interactions are being explored as a strategy for drug development. Here, we report the development of an irreversible BCL6 inhibitor TMX-2164 tha...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00111

    authors: Teng M,Ficarro SB,Yoon H,Che J,Zhou J,Fischer ES,Marto JA,Zhang T,Gray NS

    更新日期:2020-04-03 00:00:00

  • Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis.

    abstract::Stable isotope-mass spectrometry (MS)-based metabolomic profiling is a powerful technique for following changes in specific metabolite pool sizes and metabolic flux under various experimental conditions in a test organism or cell type. Here, we use a metabolomics approach to interrogate the mechanism of antibiotic act...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400349n

    authors: Prosser GA,de Carvalho LP

    更新日期:2013-12-12 00:00:00

  • Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.

    abstract::A series of bis(l-amino acid) ester prodrugs of tenofovir (TFV) were designed and synthesized as new anti-HBV agents in this work. Four compounds 11, 12a, 12d, and 13b displayed better anti-HBV activity (IC50: 0.71-4.22 μM) than the parent drug TFV. The most active compound 11 (IC50: 0.71 μM), a bis(l-valine) ester pr...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00184

    authors: Wang A,Wu S,Tao Z,Li X,Lv K,Ma C,Li Y,Li L,Liu M

    更新日期:2019-05-16 00:00:00

  • Cystine-based MBioF for Maintaining the Antioxidant-Oxidant Balance in Airway Diseases.

    abstract::Reactive oxygen species, contributing to oxidant-antioxidant imbalance, initiate damage to the airways cells, inflammatory processes, and further pathophysiological effects. Enhancing antioxidant properties is the main prophylactic and therapeutic challenge. In this work, a newly synthesized and biocompatible structur...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00468

    authors: Wiśniewski M,Bieniek A,Roszek K,Czarnecka J,Bolibok P,Ferrer P,da Silva I,Terzyk AP

    更新日期:2018-11-19 00:00:00

  • B-973, a Novel α7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and in Vivo Evaluation.

    abstract::We report here the total synthesis of B-973 (five steps), a recently identified α7 nAChR ago-PAM, its enantiomeric resolution, and its electrophysiological characterization in Xenopus oocytes to identify (-)-B-973B as the bioactive enantiomer. The asymmetric synthesis of B-973B was accomplished in 99% ee, and X-ray cr...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00407

    authors: Garai S,Raja KS,Papke RL,Deschamps JR,Damaj MI,Thakur GA

    更新日期:2018-10-11 00:00:00

  • Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.

    abstract::Continued optimization of the N-substituent in the piperidinone series provided potent piperidinone-pyridine inhibitors 6, 7, 14, and 15 with improved pharmacokinetic properties in rats. Reducing structure complexity of the N-alkyl substituent led to the discovery of 23, a potent and simplified inhibitor of MDM2. Comp...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500142b

    authors: Yu M,Wang Y,Zhu J,Bartberger MD,Canon J,Chen A,Chow D,Eksterowicz J,Fox B,Fu J,Gribble M,Huang X,Li Z,Liu JJ,Lo MC,McMinn D,Oliner JD,Osgood T,Rew Y,Saiki AY,Shaffer P,Yan X,Ye Q,Yu D,Zhao X,Zhou J,Ols

    更新日期:2014-06-30 00:00:00

  • Mitragyna speciosa: Balancing Potential Medical Benefits and Abuse.

    abstract::Mitragyna speciosa, also known as kratom, has the potential meet the need for pain medications that lack the addictiveness and overdose risk of classical opioid analgesics, such as morphine. This need is urgent because opioid addiction and overdose deaths have risen throughout diverse segments of U.S. society. Some op...

    journal_title:ACS medicinal chemistry letters

    pub_type: 社论

    doi:10.1021/acsmedchemlett.7b00298

    authors: Halpenny GM

    更新日期:2017-08-08 00:00:00

  • Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains.

    abstract::A protein structure-guided drug design approach was employed to develop small molecule inhibitors of the BET family of bromodomains that were distinct from the known (+)-JQ1 scaffold class. These efforts led to the identification of a series of substituted benzopiperazines with structural features that enable interact...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00191

    authors: Millan DS,Kayser-Bricker KJ,Martin MW,Talbot AC,Schiller SER,Herbertz T,Williams GL,Luke GP,Hubbs S,Alvarez Morales MA,Cardillo D,Troccolo P,Mendes RL,McKinnon C

    更新日期:2017-07-14 00:00:00

  • Lipidated peptidomimetics with improved antimicrobial activity.

    abstract::We report a series of lipidated α-AApeptides that mimic the structure and function of natural antimicrobial lipopeptides. Several short lipidated α-AApeptides show broad-spectrum activity against a range of clinically related Gram-positive and Gram-negative bacteria as well as fungus. Their antimicrobial activity and ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml3001215

    authors: Hu Y,Amin MN,Padhee S,Wang RE,Qiao Q,Bai G,Li Y,Mathew A,Cao C,Cai J

    更新日期:2012-07-12 00:00:00

  • Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study.

    abstract::Ataluren was reported to suppress nonsense mutations by promoting the readthrough of premature stop codons, although its mechanism of action (MOA) is still debated. The likely interaction of Ataluren with CFTR-mRNA has been previously studied by molecular dynamics. In this work we extended the modeling of Ataluren's M...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00558

    authors: Tutone M,Pibiri I,Lentini L,Pace A,Almerico AM

    更新日期:2019-02-07 00:00:00

  • From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition.

    abstract::Heat shock protein 90 (Hsp90) is a molecular chaperone that is responsible for the folding and maturation of client proteins that are associated with all ten hallmarks of cancer. Hsp90 N-terminal pan inhibitors have experienced unfavorable results in clinical trials due to induction of the heat shock response (HSR), a...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00100

    authors: Pugh KW,Zhang Z,Wang J,Xu X,Munthali V,Zuo A,Blagg BSJ

    更新日期:2020-06-11 00:00:00

  • Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.

    abstract::We report the design, synthesis, and biological evaluation of a (64)Cu-labeled histone deacetylase (HDAC) imaging probe, which was obtained by introduction of metal chelator through click reaction of HDAC inhibitor CUDC-101 and then radiolabeled with (64)Cu. The resulting (64)Cu-labeled compound 7 ([(64)Cu]7) was iden...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400191z

    authors: Meng Q,Li F,Jiang S,Li Z

    更新日期:2013-07-25 00:00:00

  • Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189.

    abstract::Late-stage oxidation using liver microsomes was applied to phosphodiesterase 2 inhibitor 1 to reduce its clearance by cytochrome P450 enzymes, introduce renal clearance, and minimize the risk for victim drug-drug interactions. This approach yielded PF-06815189 (2) with improved physicochemical properties and a mixed m...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00343

    authors: Stepan AF,Tran TP,Helal CJ,Brown MS,Chang C,O'Connor RE,De Vivo M,Doran SD,Fisher EL,Jenkinson S,Karanian D,Kormos BL,Sharma R,Walker GS,Wright AS,Yang EX,Brodney MA,Wager TT,Verhoest PR,Obach RS

    更新日期:2018-01-04 00:00:00

  • N-Acylbenzenesulfonamide Dihydro-1,3,4-oxadiazole Hybrids: Seeking Selectivity toward Carbonic Anhydrase Isoforms.

    abstract::A series of N-acylbenzenesulfonamide dihydro-1,3,4-oxadiazole hybrids (EMAC8000a-m) was designed and synthesized with the aim to target tumor associated carbonic anhydrase (hCA) isoforms IX and XII. Most of the compounds were selective inhibitors of the tumor associated hCA XII. Moreover, resolution of EMAC8000d racem...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00205

    authors: Bianco G,Meleddu R,Distinto S,Cottiglia F,Gaspari M,Melis C,Corona A,Angius R,Angeli A,Taverna D,Alcaro S,Leitans J,Kazaks A,Tars K,Supuran CT,Maccioni E

    更新日期:2017-06-21 00:00:00

  • Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S.

    abstract::In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFRL858R/T790M/C797S. One of the most promising compounds, 25g, inhibited the enzymatic activity of EGFRL858R/T790M/C797S with an IC50 value of 2.2 nM. Cell proliferation assa...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00564

    authors: Li Q,Zhang T,Li S,Tong L,Li J,Su Z,Feng F,Sun D,Tong Y,Wang X,Zhao Z,Zhu L,Ding J,Li H,Xie H,Xu Y

    更新日期:2019-05-22 00:00:00

  • Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

    abstract::Retinoid X receptor-alpha (RXRα) is implicated in the regulation of many biological processes and also represents a unique intracellular target for pharmacologic interventions. Efforts on discovery of small molecules targeting RXRα have been primarily focused on the molecules that bind to its classical ligand-binding ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml5000405

    authors: Chen F,Liu J,Huang M,Hu M,Su Y,Zhang XK

    更新日期:2014-05-14 00:00:00

  • Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.

    abstract::Substitution of rigidified A3 adenosine receptor (AR) agonists with a 2-((5-chlorothiophen-2-yl)ethynyl) or a 2-(4-(5-chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl) group provides prolonged protection in a model of chronic neuropathic pain. These agonists contain a bicyclo[3.1.0]hexane ((N)-methanocarba) ring system in p...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.5b00150

    authors: Tosh DK,Crane S,Chen Z,Paoletta S,Gao ZG,Gizewski E,Auchampach JA,Salvemini D,Jacobson KA

    更新日期:2015-05-20 00:00:00

  • Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.

    abstract::A new subseries of ROMK inhibitors exemplified by 28 has been developed from the initial screening hit 1. The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further preclinical evaluation of 28 as a new mechanism diuretic. Robust ph...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500440u

    authors: Walsh SP,Shahripour A,Tang H,Teumelsan N,Frie J,Zhu Y,Priest BT,Swensen AM,Liu J,Margulis M,Visconti R,Weinglass A,Felix JP,Brochu RM,Bailey T,Thomas-Fowlkes B,Alonso-Galicia M,Zhou X,Pai LY,Corona A,Hampton C,H

    更新日期:2015-05-07 00:00:00

  • Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.

    abstract::Despite several years of research, only a handful of β-secretase (BACE) 1 inhibitors have entered clinical trials as potential therapeutics against Alzheimer's disease. The intrinsic basic nature of low molecular weight, amidine-containing BACE 1 inhibitors makes them far from optimal as central nervous system drugs. ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00181

    authors: Oehlrich D,Peschiulli A,Tresadern G,Van Gool M,Vega JA,De Lucas AI,Alonso de Diego SA,Prokopcova H,Austin N,Van Brandt S,Surkyn M,De Cleyn M,Vos A,Rombouts FJR,Macdonald G,Moechars D,Gijsen HJM,Trabanco AA

    更新日期:2019-07-02 00:00:00

  • Diphenylpyrazoles as replication protein a inhibitors.

    abstract::Replication Protein A is the primary eukaryotic ssDNA binding protein that has a central role in initiating the cellular response to DNA damage. RPA recruits multiple proteins to sites of DNA damage via the N-terminal domain of the 70 kDa subunit (RPA70N). Here we describe the optimization of a diphenylpyrazole carbox...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml5003629

    authors: Waterson AG,Kennedy JP,Patrone JD,Pelz NF,Feldkamp MD,Frank AO,Vangamudi B,Souza-Fagundes EM,Rossanese OW,Chazin WJ,Fesik SW

    更新日期:2014-11-11 00:00:00

  • Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.

    abstract::A series of novel antifungal carboline derivatives was designed and synthesized, which showed broad-spectrum antifungal activity. Particularly, compound C38 showed comparable in vitro antifungal activity to fluconazole without toxicity to human embryonic lung cells. It also exhibited good fungicidal activity against b...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400492t

    authors: Wang S,Wang Y,Liu W,Liu N,Zhang Y,Dong G,Liu Y,Li Z,He X,Miao Z,Yao J,Li J,Zhang W,Sheng C

    更新日期:2014-02-13 00:00:00

  • Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration.

    abstract::We have employed novel fragment-based screening methodology to discover bivalent kinase inhibitors with improved selectivity. Starting from a low molecular weight promiscuous kinase inhibitor, we appended a thiol for subsequent reaction with a library of acrylamide electrophiles. Enzyme-templated screening was perform...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.5b00167

    authors: Kwarcinski FE,Steffey ME,Fox CC,Soellner MB

    更新日期:2015-07-13 00:00:00

  • Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides.

    abstract::A series of novel N-acyclic uracil analogs with linear, branched, aromatic, and cyclopropyl-alkynyl as well as heteroaryl moieties at C-5 were prepared using palladium catalyzed Sonogashira and Stille cross-coupling and evaluated against malignant tumor cell lines. C-5-Furan-2-yl uracil derivative 6 was shown to be mo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.5b00298

    authors: Meščić A,Harej A,Klobučar M,Glavač D,Cetina M,Pavelić SK,Raić-Malić S

    更新日期:2015-10-05 00:00:00

  • N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.

    abstract::A focused multiply N-methylated library of a cyclic hexapeptidic somatostatin analogue: MK678 cyclo(-MeAYwKVF-) was generated, which resulted in the unexpected observation of an efficacious tetra-N-methylated analogue, cyclo(-MeAYMewMeKVMeF-) with a potent inhibitory action on sensory neuropeptide release in vitro and...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml200032v

    authors: Chatterjee J,Laufer B,Beck JG,Helyes Z,Pintér E,Szolcsányi J,Horvath A,Mandl J,Reubi JC,Kéri G,Kessler H

    更新日期:2011-04-04 00:00:00

  • Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

    abstract::Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3Kδ isoform selective analogues with good pharmacokinetic properties. With compo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00119

    authors: Hoegenauer K,Soldermann N,Stauffer F,Furet P,Graveleau N,Smith AB,Hebach C,Hollingworth GJ,Lewis I,Gutmann S,Rummel G,Knapp M,Wolf RM,Blanz J,Feifel R,Burkhart C,Zécri F

    更新日期:2016-06-02 00:00:00

  • Multiple in Vitro Inhibition of HIV-1 Proteins by 2,6-Dipeptidyl-anthraquinone Conjugates Targeting the PBS RNA.

    abstract::We recently reported a series of 2,6-dipeptidyl-anthraquinone conjugates (AQs) as Trans-Activation Response element (TAR) RNA-binding agents able to inhibit in vitro the HIV-1 nucleocapsid (NC) protein-mediated processes. Because NC is a highly adaptable nucleic acid chaperone assisting several crucial steps along rev...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00682

    authors: Gamba E,Sosic A,Saccone I,Magli E,Frecentese F,Gatto B

    更新日期:2020-03-23 00:00:00

  • Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

    abstract::Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesira...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml100190t

    authors: Johnson DS,Stiff C,Lazerwith SE,Kesten SR,Fay LK,Morris M,Beidler D,Liimatta MB,Smith SE,Dudley DT,Sadagopan N,Bhattachar SN,Kesten SJ,Nomanbhoy TK,Cravatt BF,Ahn K

    更新日期:2011-02-10 00:00:00

  • Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor.

    abstract::Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-XL inhibitor that selectively and potently induces apoptosis in BCL-XL-dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-XL inhibitor A-1155463 using structure-based drug design. Key design ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00568

    authors: Wang L,Doherty GA,Judd AS,Tao ZF,Hansen TM,Frey RR,Song X,Bruncko M,Kunzer AR,Wang X,Wendt MD,Flygare JA,Catron ND,Judge RA,Park CH,Shekhar S,Phillips DC,Nimmer P,Smith ML,Tahir SK,Xiao Y,Xue J,Zhang H,Le PN

    更新日期:2020-03-30 00:00:00

  • gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension.

    abstract::Primary open angle glaucoma is the second most common cause of blindness worldwide. Nitric oxide has recently received particular attention as a potential antiglaucoma agent. In this work, gem-dinitroalkyl benzenes are evaluated for their capability to act as a new class of IOP lowering agents. These derivatives have ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00264

    authors: Blangetti M,Rolando B,Marini E,Chegaev K,Guglielmo S,Lazzarato L,Lucarini L,Masini E,Fruttero R

    更新日期:2017-09-13 00:00:00